ATE305312T1 - Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten - Google Patents

Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten

Info

Publication number
ATE305312T1
ATE305312T1 AT01926985T AT01926985T ATE305312T1 AT E305312 T1 ATE305312 T1 AT E305312T1 AT 01926985 T AT01926985 T AT 01926985T AT 01926985 T AT01926985 T AT 01926985T AT E305312 T1 ATE305312 T1 AT E305312T1
Authority
AT
Austria
Prior art keywords
agents
naphthalimide
antiproliferative agent
antiproliferative
host
Prior art date
Application number
AT01926985T
Other languages
English (en)
Inventor
Dennis M Brown
Original Assignee
Chemgenex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemgenex Pharmaceuticals Inc filed Critical Chemgenex Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE305312T1 publication Critical patent/ATE305312T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
AT01926985T 2000-04-12 2001-04-12 Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten ATE305312T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19710300P 2000-04-12 2000-04-12
PCT/US2001/012169 WO2001078705A2 (en) 2000-04-12 2001-04-12 Compositions containing a naphthalmide and an antiproliferative agent

Publications (1)

Publication Number Publication Date
ATE305312T1 true ATE305312T1 (de) 2005-10-15

Family

ID=22728064

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01926985T ATE305312T1 (de) 2000-04-12 2001-04-12 Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten

Country Status (10)

Country Link
US (2) US6630173B2 (de)
EP (1) EP1274458B1 (de)
JP (1) JP2003530431A (de)
AT (1) ATE305312T1 (de)
AU (1) AU5348301A (de)
CA (1) CA2404278C (de)
DE (1) DE60113666T2 (de)
ES (1) ES2248312T3 (de)
HK (1) HK1052874B (de)
WO (1) WO2001078705A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4929436B2 (ja) * 2000-03-15 2012-05-09 ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド セファロタキシンアルカロイド組成物およびその使用
JP2003530431A (ja) * 2000-04-12 2003-10-14 ケムジェネックス・セラピューティクス・インコーポレイテッド ナフタルイミドおよび抗増殖性剤を含有する組成物
US7135481B2 (en) * 2000-04-12 2006-11-14 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US20060211648A1 (en) * 2000-04-12 2006-09-21 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
US6693198B2 (en) 2002-04-22 2004-02-17 Xanthus Life Sciences, Inc. Amonafide salts
US20050239816A1 (en) * 2002-04-22 2005-10-27 Xanthus Life Sciences, Inc. Amonafide salts
WO2003090681A2 (en) * 2002-04-24 2003-11-06 Research Development Foundation SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS
WO2004004716A1 (en) * 2002-07-08 2004-01-15 Chemgenex Pharmaceuticals Limited Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof
JP2006501199A (ja) * 2002-07-17 2006-01-12 ケムジェネックス・ファーマシューティカルズ・リミテッド ホモハリングトニンを含むセファロタキシンの製剤および投与方法
AU2003254120B2 (en) * 2002-07-22 2009-09-10 Teva Pharamceuticals International Gmbh Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
WO2005074599A2 (en) * 2004-01-30 2005-08-18 Chemgenex Pharmaceuticals, Inc. Naphthalimide dosing by n-acetyl transferase genotyping
JP2008501719A (ja) * 2004-06-04 2008-01-24 ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド ナフタルイミドおよびｐａｒｐ−１インヒビターを使用する細胞増殖性疾患の処置方法
AU2006213915A1 (en) * 2005-02-10 2006-08-17 Chemgenex Pharmaceuticals, Inc. Medical devices
JP5550546B2 (ja) * 2007-04-13 2014-07-16 ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド 経口セファロタキシン剤形

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183821A (en) * 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
US5420137A (en) * 1989-07-11 1995-05-30 Knoll Ag Amonafide salts
FR2673944B1 (fr) * 1991-03-13 1995-03-10 Sanofi Elf Derives de l'1,8-naphtalimide, leur procede de preparation et les compositions pharmaceutiques les contenant.
JP2002511878A (ja) * 1997-07-01 2002-04-16 アセロジエニクス・インコーポレイテツド 抗酸化剤による過増殖状態の治療の増強
JP4929436B2 (ja) * 2000-03-15 2012-05-09 ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド セファロタキシンアルカロイド組成物およびその使用
CA2403490A1 (en) * 2000-03-21 2001-10-25 Atherogenics, Inc. N-substituted dithiocarbamates for the treatment of biological disorders
JP2003530431A (ja) * 2000-04-12 2003-10-14 ケムジェネックス・セラピューティクス・インコーポレイテッド ナフタルイミドおよび抗増殖性剤を含有する組成物

Also Published As

Publication number Publication date
DE60113666T2 (de) 2006-06-14
US20040047918A1 (en) 2004-03-11
AU5348301A (en) 2001-10-30
EP1274458B1 (de) 2005-09-28
WO2001078705A2 (en) 2001-10-25
WO2001078705A3 (en) 2002-06-20
CA2404278A1 (en) 2001-10-25
EP1274458A2 (de) 2003-01-15
US20020025916A1 (en) 2002-02-28
HK1052874B (zh) 2006-05-04
DE60113666D1 (de) 2005-11-03
ES2248312T3 (es) 2006-03-16
HK1052874A1 (en) 2003-10-03
CA2404278C (en) 2010-03-23
JP2003530431A (ja) 2003-10-14
US6630173B2 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
ATE305312T1 (de) Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten
Rossetti et al. Perylene diimides with different side chains are selective in inducing different G-quadruplex DNA structures and in inhibiting telomerase
PT1075477E (pt) Novos n-oxidos de benzonaftiridina
HK1054967A1 (en) Method of amplifying nucleic acid by using double-stranded nucleic acid as template
AU7878301A (en) Method of amplifying nucleic acid
ATE309224T1 (de) Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
ATE229955T1 (de) Substituierte 1,8-naphthyridin-4(1h)-one als phosphodiesterase 4-inhibitoren
AP2001002319A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
AU2002365912A8 (en) Pyrophosphorolysis and incorporation of nucleotide method for nucleic acid detection
WO2000072799A3 (en) Method and compositions for treating the inflammatory response
WO2001004357A3 (en) Generic sbe-fret protocol
ATE330611T1 (de) Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung
AU2003280603A8 (en) Method of amplifying nucleic acid
AU5479501A (en) Polyamide nucleic acid derivatives, agents and methods for producing them
HK1040769A1 (en) Method for detection and quantification of specific nucleic acid.
WO2001091740A3 (en) Compositions containing naphthaquinone and an antiproliferative agent
ATE411815T1 (de) Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung
IL147281A0 (en) Methods of treating fungal infections with inhibitors of nad synthetase enzyme
WO2007095639A3 (en) Napht alimide compositions and uses thereof
Aviñó et al. Parallel-stranded hairpins containing 8-aminopurines. Novel efficient probes for triple-helix formation
AP2002002417A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
HUP0303953A2 (hu) Eljárás tumorok kezelésére alkalmas gyógyszerkészítmény előállítására tegafur, uracil, folinsav és ciklofoszfamid alkalmazásával
Okamoto et al. Unique hole-Trapping property of the degenerate base, 2-amino-7-deazaadenine
WO2001080842A3 (en) Compositions comprising a methylnogarol in combination with an antiproliferative agent

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties